jueves, 19 de febrero de 2026
I took part in a 2012 psilocybin trial. What I’m seeing now horrifies me For-profit companies are discarding central components of psychedelic therapy
https://www.statnews.com/2026/02/19/psychedelic-therapy-more-than-just-drugs/
By Erica RexFeb. 19, 2026
Rex is the author of the new book “Seeing What Is There: My Search for Sanity in the Psychedelic Era.”
My biggest GLP-1 ethical problem: patients who don’t want to stop We’ve gone from weight loss drug shortages to a problem of excess — and eating disorders
https://www.statnews.com/2026/02/19/glp-1-weight-loss-drugs-eating-disorders-doctor/
By Jody DushayFeb. 19, 2026
Dushay is an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center.
Should semen analysis become the Pap smear for men? Some men’s health experts say yes Unusual sperm count or motility can flag risk of diseases as well as possible fertility problems
https://www.statnews.com/2026/02/19/semen-analysis-startups-pitch-male-version-pap-smear/
By Annalisa MerelliFeb. 19, 2026
Contributing Writer
miércoles, 18 de febrero de 2026
Oral weight loss ingredient may have adverse biological effects for the gut and beyond
https://www.news-medical.net/news/20260217/Oral-weight-loss-ingredient-may-have-adverse-biological-effects-for-the-gut-and-beyond.aspx
A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and beyond.
European report: Antimicrobial resistance remains widespread in foodborne bacteria
https://www.news-medical.net/news/20260218/European-report-Antimicrobial-resistance-remains-widespread-in-foodborne-bacteria.aspx
Antimicrobial resistance (AMR) in common foodborne bacteria such as Salmonella and Campylobacter continues to be a public health concern across Europe, according to a new joint report from the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC).
Researchers find new way to halt leukemia stem cell growth
https://www.news-medical.net/news/20260218/Researchers-find-new-way-to-halt-leukemia-stem-cell-growth.aspx
In a new study published in Nature Communications, a research team at the University of Oslo have examined how cancer cells develop in the bone marrow and whether it might be possible to stop them. The study finds a way to stop malignant stem cells. The researchers believe their findings could open up new avenues for treatment in the future.
Diet and the Reprogramming of Innate Immune Memory
https://www.news-medical.net/health/Diet-and-the-Reprogramming-of-Innate-Immune-Memory.aspx
Emerging research reveals how specific dietary components may reshape innate immune memory at the level of metabolism and chromatin, offering new insight into the biological interface between nutrition and immune resilience.
How Heat Stress Affects the Human Body at the Cellular Level
https://www.news-medical.net/health/How-Heat-Stress-Affects-the-Human-Body-at-the-Cellular-Level.aspx
Rising temperatures disrupt human cellular stability by impairing proteostasis, altering mitochondrial function, reprogramming gene expression, and reshaping immune responses, ultimately shifting cells from adaptive survival toward inflammation and programmed death under sustained stress.
Ovarian Aging Explained: Biological Age, Fertility, and Epigenetic Markers
https://www.news-medical.net/health/Ovarian-Aging-Explained-Biological-Age-Fertility-and-Epigenetic-Markers.aspx
Epigenetic clocks provide a molecular framework for assessing biological ovarian age by integrating DNA methylation patterns with hallmarks of reproductive aging. While these clocks show moderate predictive value for fertility outcomes such as IVF success, they currently function best as complementary research tools rather than standalone clinical diagnostics.
Can mobile apps change how we eat?
https://www.news-medical.net/news/20260218/Can-mobile-apps-change-how-we-eat.aspx
From eco-score apps to immersive virtual supermarkets, researchers explore whether technology can nudge people toward healthier and more sustainable eating habits, and why stronger, longer-term evidence is still urgently needed.
Living rare: finding my voice with diffuse systemic scleroderma
https://rarerevolutionmagazine.com/living-rare-finding-my-voice-with-diffuse-systemic-scleroderma/
Kristina Hamilton is a patient advocate living with diffuse systemic scleroderma. Diagnosed in 2022, she shares her lived experience to raise awareness of rare and often misunderstood autoimmune diseases. Through storytelling and advocacy, Kristina is committed to helping others feel seen, less alone and empowered to use their voices within the rare disease community
Toward dignity-centred ethics in the treatment of longstanding and severe eating disorders: a lived experience-led narrative review James Downs* [1] , Marissa Adams [2]
https://www.academia.edu/2997-9196/2/4/10.20935/MHealthWellB7942
Longstanding and severe eating disorders (LSEDs) are frequently marked by medical risk, therapeutic impasse, and exclusion from standard care pathways. Yet insufficient attention has been paid to the ethical dimensions of treatment for those with complex and longstanding illness trajectories, in particular from the perspective of those with lived experience. This paper aims to address this gap as a lived-experience-authored narrative review focused on the concept of dignity as a guiding value of ethical care in LSEDs. Informed by critical interpretive synthesis, narrative ethics, and reflective practice methods, the authors integrate multiple sources of evidence. They adopt a lens of epistemic injustice, situating subjective knowledge alongside empirical research findings and the wider conceptual and ethical considerations of treatment provision. The findings identify recurring patterns of undignified care in the treatment of LSEDs, including the normalisation of neglect, coercive practices, and exclusionary models of treatment. Principles and practical steps are outlined to inform dignity-affirming care, which include prioritising relational safety, co-produced decision-making, and re-medicalisation of LSEDs in ways that do not sacrifice autonomy. Ultimately, the authors determine that a dignity-centred approach to LSEDs requires a fundamental shift in how we understand risk, chronicity, and the place of lived experience in clinical ethics. This paper offers a conceptual and methodological framework to support that shift, calling for collective responsibility and structurally embedded forms of care that respect the knowledge, rights, and needs of those most affected by LSEDs.
A new dawn for osteoporosis drug development The Lancet Diabetes & Endocrinology ++... ++
A new dawn for osteoporosis drug development
The Lancet Diabetes & Endocrinology
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00011-2/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 14Number 3p187-274, e3-e6
https://www.thelancet.com/journals/landia/issue/vol14no3/PIIS2213-8587(26)X2001-0
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial
Albert Wiegman, MD PhDa a.wiegman@amsterdamumc.nl ∙ Prof Amy L Peterson, MD MSb ∙ Prof Eric Bruckert, MDc ∙ Joep C Defesche, PhDd ∙ Anja Schweizer, PhDe ∙ Prof Jean Bergeron, MDf ∙ et al.
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00351-1/abstract?dgcid=raven_jbs_etoc_feature_landia
The Lancet Summit: shaping the future of diabetes prevention
Nov 30–Dec 2, 2026 | Sitges, Spain
https://thelancetsummit.com/diabetes-prevention/index.html
RISE Together: Data Sharing Across the Rare Disease Ecosystem March 30, 2026 — 9:00AM–4:30PM
https://healthpolicy.duke.edu/events/rise-together-data-sharing-across-rare-disease-ecosystem?utm_medium=email&utm_source=govdelivery
Registration is now open to attend the FDA Rare Disease Innovation Hub’s March 30th Rare Disease Innovation, Science, and Exploration (RISE) Workshop to explore data sharing as it pertains to informing development and regulatory review for rare disease therapies.
This public workshop will focus on clarifying possible avenues for data sharing and the types of data that can be shared (e.g., safety information, real-world evidence, and deidentified patient data).The workshop will also discuss: the promotion of data sharing practices and structures for facilitating data sharing among rare disease drug development stakeholders; examples of the impact of data sharing in regulatory submissions; a priori considerations for the collection and sharing of high quality data; some of the logistical and legal challenges encountered in data sharing; and whether there are ways that FDA might support data sharing, within the bounds of its authority.
Gain a deeper knowledge of endocrine resistance mechanisms and treatment selection for ER-positive/HER2-negative metastatic breast cancer after progression
https://www.medscape.org/advances/oral-serds-2025a1000o90?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_437674.35_ace_launch
ER-Positive/HER2-Negative Metastatic Breast Cancer: Navigating Endocrine Resistance and Expanding Treatment Options
Endocrine therapy remains the cornerstone of treatment for ER-positive/HER2-negative metastatic breast cancer, yet both intrinsic and acquired resistance ultimately limit its long-term success. Resistance arises through diverse mechanisms—including activating ESR1 mutations, crosstalk with growth factor signaling pathways, and epigenetic changes—that allow tumor cells to bypass estrogen receptor blockade. New oral selective estrogen receptor degraders (SERDs) are designed to directly target and degrade the estrogen receptor, offering the potential to overcome ESR1-mediated resistance while providing the convenience of once-daily dosing. A deep understanding of endocrine resistance mechanisms is essential to identify which patients will derive the greatest benefit, to inform rational combination strategies, and ultimately to extend disease control and improve quality of life in this challenging clinical setting.
This educational resource designed with the oncology team in mind, including oncologists, obstetrician/gynecologists, pathologists, nurse practitioners, nurses, and pharmacists, offers CME activities that feature insights from leading experts, along with engaging slide kits, clinical articles, and links to valuable resources. Together, these materials create a dynamic community of learning focused on enhancing patient care and achieving positive outcomes.
Public Meeting: FDA Rare Disease Day 2026 February 23, 2026
https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/public-meeting-fda-rare-disease-day-2026-02232026?utm_medium=email&utm_source=govdelivery
FDA is hosting a virtual public meeting on February 23rd in observance of Rare Disease Day. We encourage you to participate and help advance rare disease treatment by sharing your treatment experiences.
As this important day approaches, we invite you to contribute to CURE ID. Developed by FDA and NIH, CURE ID is a free platform where patients, caregivers, and clinicians can report their experiences using existing drugs in new ways to treat rare diseases. Approved reports are displayed to the public, once personal details have been removed from the data. This enables the community to contribute to a public database that may help identify new treatment options.
Help find treatments for challenging diseases
CURE ID is a free platform to share novel uses of existing drugs and explore what others have tried. The goal is to identify potential treatments for diseases without good treatment options.
https://cure.ncats.io/home?utm_medium=email&utm_source=govdelivery
Health Literacy and HIV: Understanding the Tools in the HIV Prevention Toolbox
https://www.hiv.gov/blog/health-literacy-and-hiv-understanding-the-tools-in-the-hiv-prevention-toolbox?j=2895435&sfmc_sub=6992026&l=6498_HTML&u=71999665&mid=100006181&jb=0
Increasing health literacy is something we should promote year round, including health literacy about HIV prevention. When we work to increase people’s health literacy about HIV prevention by empowering them with information, they can take charge of their health. Our latest blog post does this by making the tools in the HIV prevention toolbox easy to understand and accessible.
martes, 17 de febrero de 2026
Post-Traumatic Stress Disorder and Alcohol Consumption: Biological Mechanisms of Stress Resilience to Subsequent Alcohol Consumption Quilla C. Flanagan-Burt,* Celia Middleton,* and Junghyup Suh
https://arcr.niaaa.nih.gov/volume/46/1/post-traumatic-stress-disorder-and-alcohol-consumption-biological-mechanisms-stress?utm_source=arcr-email&utm_medium=email&utm_campaign=suh-2026-02&utm_content=arcr-listserv
PURPOSE: Resilience is crucial in mitigating the risk of stress-related health issues. Although many people can adapt to adverse stress or trauma, stress exposure can increase the risk of health issues, including obesity, cardiovascular disease, and digestive illnesses. Some individuals may even develop debilitating conditions, such as post-traumatic stress disorder (PTSD). People with PTSD often struggle to adapt, sometimes turning to alcohol to cope, which can lead to alcohol use disorder (AUD), characterized by excessive alcohol-seeking and dependence. Understanding the biological underpinnings of resilience, therefore, is a key to preventing both PTSD and AUD. Recent research has uncovered the neurobiological traits that protect against the development of stress-induced alcohol dependence. Studies have shown that proactive coping and a lack of stress-related symptoms are associated with resilience. Preclinical studies, especially in rodents, have provided deeper insights into how stress impacts alcohol-seeking behaviors. Research has shown that resilience involves adaptive changes at the molecular, cellular, neural circuit, and systems levels. This review aims to integrate this research to better understand what makes people vulnerable to stress and alcohol consumption, highlighting aspects frequently overlooked in clinical models.
Introducing the CAHPS End-of-Life Care Survey (Webcast) January 15, 2026
https://www.ahrq.gov/cahps/news-and-events/events/webinar-end-of-life-survey-011526.html
This webcast explored the purpose and development of AHRQ’s newest Consumer Assessment of Healthcare Providers and Systems (CAHPS®) End-of-Life Care Survey. Experts discussed why this new survey was created, how it was tested, and the best practices for its implementation. The session also featured insights from Kaiser Permanente, highlighting the organization’s experience using the survey during its field-testing phase.
Speakers:
Jonathan Bakdash, Ph.D., Agency for Healthcare Research and Quality
Rebecca Anhang-Price, Ph.D., RAND
Melissa Bradley, RAND
Susan Wang, MD, Kaiser Permanente
Stephanie Fry, CPXP, (Moderator), Westat
https://www.ahrq.gov/cahps/surveys-guidance/end-of-life/index.html
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers April 15, 2026 | 1:00 PM - 2:30 PM ET
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
April 15, 2026
https://www.fda.gov/drugs/news-events-human-drugs/expanded-access-investigational-drugs-treatment-use-questions-and-answers-04152026?utm_medium=email&utm_source=govdelivery
Join the Small Business and Industry Assistance (SBIA) program for an informative webinar on the guidance, Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers. Expanded access is a pathway for patients with serious or immediately life-threatening diseases or conditions to gain access to investigational drugs for treatment outside of clinical trials when no comparable or satisfactory alternative treatment options are available.
The primary goal of this event is to provide attendees with a comprehensive understanding of this pathway, including the regulatory requirements and FDA’s recommendations. The session will detail the three categories of Expanded Access (EA): individual patient, intermediate-size population, and treatment INDs and protocols, and will increase participants’ understanding of the criteria, submission requirements, and responsibilities of all parties involved.
Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers
October 2025
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers-0?utm_medium=email&utm_source=govdelivery
A new path for assisted dying in Europe: France's middle way The Lancet Regional Health – Europe ++ ++...
Effectiveness of an environmental nutrition and physical activity intervention in early childhood education and care settings (NAPSACC UK): a multicentre cluster randomised controlled trial
Ruth Kippinga ruth.kipping@bristol.ac.uk ∙ Sharon Anne Simpsonb ∙ Kim Hannama ∙ Peter S. Blaira ∙ Russell Jagoa ∙ Corby K. Martinc ∙ et al.
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00342-4/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz--4YhCEdNZwP-0U8QNPvF_EznZOCHShSdVDTp8yp2wnznk190DfzStGA3jUwmLv6-9sAet6xn2H2rjBCY0hYSvqpA6sTQ&_hsmi=403964996&utm_content=403598960&utm_source=hs_email
A multimodal individualized long-term intervention to prevent functional decline after stroke (LAST-long): a single blinded randomised controlled trial
Torunn Askima,b,j torunn.askim@ntnu.no ∙ Sara Rise Langloa,c,j ∙ Elin Bergha,d ∙ Øystein Døhla,e ∙ Hanne Ellekjæra,b ∙ Anne Hokstada,c ∙ et al.
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00323-0/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9YaOmCpScK-79DIiMVifSCYJJ3QxYaQssUoJQNjcAKC0PGgw2AMWA37KxkIVHKkKpglDbH5R8KjQahgxA-2umK3t7gYg&_hsmi=403964996&utm_content=403598960&utm_source=hs_email
A new path for assisted dying in Europe: France's middle way
The Lancet Regional Health – Europe
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00029-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz--wsNlVf4WPY7SmYU3HWiScR6uCOfO1BfRc-_NhgaFD2j0Ao5qMWZH_m-gB-ETxkkOQelXYFgbEcVGwNus-37tsnR0H1Q&_hsmi=403964996&utm_content=403598960&utm_source=hs_email
Feb 2026
Volume 61
https://www.thelancet.com/journals/lanepe/issue/vol61nonull/PIIS2666-7762(25)X0012-0
Editorial p99 Lifting the veil on tobacco industry influence The Lancet Respiratory Medicine +++ +...
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial
Prof David J Jackson, FRCPa david.jackson47@nhs.net ∙ Prof Njira L Lugogo, MDb ∙ Prof Mark Gurnell, PhDc,d ∙ Prof Liam G Heaney, MDe ∙ Prof Stephanie Korn, MDf,g ∙ Prof Guy Brusselle, MDh ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00359-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanres&utm_campaign=update-lanres&utm_medium=email&_hsenc=p2ANqtz-8WDqTrpJQhwPRA-h3mmwGaFzc18kP9uiQXYFW8EPg5NjH_8uQXTGqEdIFvvumDz7iDD1-72EZdwqn67W1puLcE-Er_ew&_hsmi=403947918&utm_content=403597881&utm_source=hs_email
Hospital and long-term outcomes for subglottic suction and polyurethane cuff versus standard endotracheal tubes in emergency intubation (PreVent 2): a randomised controlled phase 2 trial
Prof Miriam M Treggiari, MD PhDa,c miriam.treggiari@duke.edu ∙ Emily S Sharp, PhDc ∙ Tetsu Ohnuma, MD PhDa ∙ Elaine C Fajardo, MDd ∙ Ani Aydin, MDe ∙ Prof Shamsuddin Akhtar, MDf ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00294-2/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz-_z21Zfw2SBGyyQ2y9s6XukT1sJLsLxE5T_GSvGmdy7w58Z8bwW-vn7X8AWzl0GO_7Werdeh2hU1qEdr647B2XTbRkbqw&_hsmi=403947918&utm_content=403597881&utm_source=hs_email
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
Jia Zhong, MDa,* ∙ Prof Jun Zhao, MDb,* ∙ Prof Jianchun Duan, MDa,c,* ∙ Prof Jian Fang, MDd ∙ Kailun Fei, MDa ∙ Xiaoyan Li, MDe ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00258-9/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz--6ZFJHJu2e9QTx2-cCcHo0QFzLkMaVsmv-vio7DUcqU_hRN1Vii8jHl1b096ZX5niiDDcGR736WyHUQD83sdcM75CYIA&_hsmi=403947918&utm_content=403597881&utm_source=hs_email
Editorial
p99
Lifting the veil on tobacco industry influence
The Lancet Respiratory Medicine
https://www.thelancet.com/journals/lanres/issue/vol14no2/PIIS2213-2600(26)X2001-X
Safeguarding women and girls in the age of AI The Lancet Global Health ++... ++
Safeguarding women and girls in the age of AI
The Lancet Global Health
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00030-6/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 14Number 3e311-e474
https://www.thelancet.com/journals/langlo/issue/vol14no3/PIIS2214-109X(26)X2001-0
Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study
Oliver Langselius, PhDa,b,c,* langseliuso@iarc.who.int ∙ Harriet Rumgay, PhDa,* ∙ Jérôme Vignat, MSca ∙ Hadrien Charvat, PhDa ∙ Mark J Rutherford, PhDa,d ∙ Allini Mafra, PhDe ∙ et al.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00494-2/fulltext?dgcid=raven_jbs_etoc_feature_langlo
Effective cataract surgical coverage in adults aged 50 years and older: empirical estimates from population-based surveys in 68 countries and modelled estimates for 2000–30
Ian McCormick, PhDa ian.mccormick@lshtm.ac.uk ∙ Yamna Ouchtar, PhDb ∙ David Macleod, PhDb ∙ Anna Harte, PhDc ∙ Maria Vittoria Cicinelli, MDd ∙ Tabassom Sedighi, PhDe ∙ et al
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00435-8/fulltext?dgcid=raven_jbs_etoc_feature_langlo
Join us for Webinar on Addressing Veteran Substance Use: Promoting Recovery Through Collaboration and Compassion March 3, 2–3:30 p.m. ET
https://prainc.zoom.us/webinar/register/WN_ez-Bdfv3QTGgOxpvuFUtCw?utm_source=SAMHSA&utm_campaign=a8e747a6f3-EMAIL_CAMPAIGN_2026_01_26_02_20_COPY_01&utm_medium=email&utm_term=0_-b17f140eb4-167840245#/registration
Supporting Veterans means strengthening recovery pathways. Attend this free webinar and learn how cross-system collaboration improves outcomes in substance use care.
Join leaders from the Department of Veterans Affairs, SAFE Project, and Oregon Health Authority leaders for a focused discussion on effective, evidence-informed approaches to supporting Veterans and Service Members affected by substance use.
Key learning objectives:
Key trends in Veteran substance use and co-occurring conditions
Proven treatment and recovery models
Practical strategies for cross-system collaboration
Featured Speakers:
Jay A. Gorman, Ph.D., Department of Veterans Affairs
Adam Swift, SAFE Project
Susan Davis, LPC, CADC I, Oregon Health Authority
This webinar will be followed by a learning community series exploring each of these topics in greater detail. If you are interested, you can get further information via our monthly newsletter or from our SMVF TA Upcoming Events.
Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial Biotech firm aims to win FDA approval based on study’s results
https://www.statnews.com/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/
By Adam FeuersteinFeb. 17, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Editorial p137 Cancer: another casualty of geopolitical unrest? The Lancet Oncology +++ +...
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
Liang Zhang, MDa ∙ Xiqin Zhang, BSb ∙ Lin Wu, MDc ∙ Wenqun Xing, BSd ∙ Chunling Liu, MSe ∙ Prof Peng Zhang, MDf ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00643-6/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-9HfIlNZWEKCqhm6q6IY9r4FCJ7kgJprjNHTTJ0sy5IryHglgZ6i5oWbafz9c-4Tdatg8Wpigj0aXUKuF-7NzUYoHC3-w&_hsmi=403942809&utm_content=403597534&utm_source=hs_email
Expert recommendations for the conduct and appraisal of qualitative research in oncology
Erica C Kaye, MDa,* erica.kaye@stjude.org ∙ Jori Bogetz, MDd,e,* ∙ Krysta S Barton, PhDf ∙ Cynthia J Bell, PhDg ∙ Emily E Johnston, MDh,i ∙ Rachel A Pozzar, PhDj ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-_Kk6IiatuW32C9-VEm3Ut1uvzC5wAOq5c43xD9SNoOj5LE193z8t1-mOZRZZPgFtmx-ibwOua4rSkAQ8kmJWw8JpHmzg&_hsmi=403942809&utm_content=403597534&utm_source=hs_email
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment
Dirk De Ruysscher ∙ Pim J J Damen p.damen@erasmusmc.nl ∙ Lizza E L Hendriks lizza.hendriks@mumc.nl ∙ Stephanie P L Saw
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00756-9/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-80oGo9Ar3KkITkJW6JZX5vnE_6ECt0OxfpQJsyOssMMWV0oohxODo-pd064x0jNIDFtu8Wsh8L72w-pLEA0Il0OjLQcw&_hsmi=403942809&utm_content=403597534&utm_source=hs_email
Editorial
p137
Cancer: another casualty of geopolitical unrest?
The Lancet Oncology
https://www.thelancet.com/journals/lanonc/issue/vol27no2/PIIS1470-2045(26)X2001-0
Can parasites influence insulin signaling and development of diabetes mellitus? Gumpeny Ramachandra Sridhar* [1] , Srinivas Botta [2] , Gumpeny Lakshmi [3] ++...
https://www.academia.edu/2837-4010/4/1/10.20935/AcadBiol8088
While type 2 diabetes mellitus (T2DM) is a global health challenge, parasitic infections are prevalent in tropical and subtropical regions. There is evidence of a complex relationship between schistosomiasis and T2DM, implicating helminth infections as potential modulators of diabetes and metabolic syndrome. It was observed that individuals with a history of schistosomiasis had lower prevalence of diabetes, insulin resistance, and metabolic syndrome. Mechanistic explanations suggest that helminths modulate host immunity, skewing responses towards an anti-inflammatory phenotype (Th2 cytokine dominance) and promoting regulatory macrophage populations (M2-like phenotype). Such immune modulation may prevent inflammation-driven insulin resistance, a hallmark of T2DM. Additionally, helminth infections influence host lipid metabolism and gut microbiota, both crucial for metabolic regulation. Despite largely protective findings, some reports present contrasting associations, underscoring the complexity of helminth–host metabolic interactions. Current research is focused on harnessing helminth-derived immunomodulatory molecules and excretory–secretory products as novel therapeutic agents for metabolic diseases. Clinical trials using controlled helminth infections have shown preliminary metabolic benefits, though significant clinical, cultural, and regulatory barriers remain. Overall, elucidating the intricate interplay between helminthic infections and T2DM opens promising therapeutic avenues, potentially redefining approaches for preventing and managing metabolic diseases.
The need for echocardiographic reference values in adults over 80 years of age
Miguel Quintana, Mira Carling, Anders Olofsson, Dag Isaksson, Jenny Fahlen, Elin Kärrman, Fredrik Pihl, Roland Forsberg, Björn Persson, Alen Lovric, Thomas Gustafsson, Karin Bouma
Volume 4, Issue 1
https://www.academia.edu/journals/academia-biology/articles?source=journal-top-nav
lunes, 16 de febrero de 2026
GLP-1 drugs in haematology: beyond weight loss The Lancet Haematology + +...
GLP-1 drugs in haematology: beyond weight loss
The Lancet Haematology
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00002-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz--JBgPfmSamPIENTFgWS6pqIxvOW_SnhPv5bxv_TV-eYyU3NeY8ierOsQhFbPIxh7DNdx9FMwnjIyMbrlm4-6vM5wwPaQ&_hsmi=403816799&utm_content=403596743&utm_source=hs_email
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) began as therapies for type 2 diabetes but have become a breakthrough therapy for obesity, redefining its treatment and broader metabolic landscape. They have lit up medicine, popular culture, and global markets as new benefits and controversies unfold, with no field of medicine immune. By mimicking GLP-1 physiology, these drugs have come a long way, from the US Food and Drug Administration approval to treat type 2 diabetes in 2005 to approval to treat obesity in 2014, peaking with the 2021 subcutaneous weekly semaglutide regimen that delivered unprecedented weight loss. The excitement has only grown as trials reveal benefits in people with cardiovascular disease and sleep apnoea, and as emerging data hint at benefits in metabolic-dysfunction-associated liver disease, chronic kidney disease, peripheral artery disease, and osteoarthritis. In light of this growing evidence, it is reasonable to ask whether these agents could have an effect on haematological conditions.
Feb 2026
Volume 13Number 2e55-e118
https://www.thelancet.com/journals/lanhae/issue/vol13no2/PIIS2352-3026(26)X2001-4
RARE Revolution RARE Bite
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=5fddfc62-9dc6-47bf-aa6a-922d41bce312&pnum=76
Nadine Lipworth shares an all-too-familiar tale. She illustrates in real colour the true cost of inaction and the often untold trauma families face when confronted by that lack of action and an absence of a diagnosis. This is Nadine and her husband, Dave’s, journey so far while saving Sasha.
Machine learning model demonstrates insulin resistance as a risk factor for 12 types of cancer
https://www.news-medical.net/news/20260216/Machine-learning-model-demonstrates-insulin-resistance-as-a-risk-factor-for-12-types-of-cancer.aspx
Insulin resistance - when the body doesn't properly respond to insulin, a hormone that helps control blood glucose levels - is one of the fundamental causes of diabetes. In addition to diabetes, it is widely known that insulin resistance can lead to cardiovascular, kidney and liver diseases. While insulin resistance is tightly associated with obesity, it has been difficult to evaluate insulin resistance itself in the clinic. For the first time, researchers including those from the University of Tokyo applied a machine learning-based prediction model of insulin resistance to half a million participants from the UK Biobank and demonstrated that insulin resistance is a risk factor for 12 types of cancer.
Optimization of CAR T cells to destroy solid tumors
https://www.news-medical.net/news/20260216/Optimization-of-CAR-T-cells-to-destroy-solid-tumors.aspx
A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors.
Unlocking the potential of phytochemicals in rheumatoid arthritis treatment
https://www.news-medical.net/news/20260216/Unlocking-the-potential-of-phytochemicals-in-rheumatoid-arthritis-treatment.aspx
Announcing a new article publication for BIO Integration journal. In recent years, phytochemicals and medicinal plants have increasingly been used to treat autoimmune diseases, such as rheumatoid arthritis (RA). RA, a systemic inflammatory disease, is a chronic condition that affects primarily the joints, which are lined by synovial membranes, and leads to pain, diminished mobility, and joint deterioration.
Diet and the Reprogramming of Innate Immune Memory
https://www.news-medical.net/health/Diet-and-the-Reprogramming-of-Innate-Immune-Memory.aspx
Emerging research reveals how specific dietary components may reshape innate immune memory at the level of metabolism and chromatin, offering new insight into the biological interface between nutrition and immune resilience.
Eating more plant-based foods may lower breast cancer risk, major international study indicates
https://www.news-medical.net/news/20260215/Eating-more-plant-based-foods-may-lower-breast-cancer-risk-major-international-study-indicates.aspx
Large international cohort data suggest plant-forward eating patterns and certain micronutrients may be linked to lower breast cancer risk and improved survival, highlighting diet as a potentially modifiable factor worth further investigation.
Experimental stem cell therapy aims to repair brain circuits in Parkinson’s A Phase 1 trial at Keck Medicine of USC is testing whether implanted iPSC-derived neurons can restore dopamine signaling and improve motor function.
https://www.drugdiscoverynews.com/experimental-stem-cell-therapy-aims-to-repair-brain-circuits-in-parkinson-s-17009
Parkinson’s disease (PD) is the fastest-growing neurodegenerative disorder worldwide, affecting an estimated one percent of individuals over the age of 60. In the US, more than one million people live with the disease, and roughly 90,000 new cases are diagnosed each year.
Expert-Driven, Patient-Focused: Mastering Personalized Care for HER2-Low Metastatic Breast Cancer Authors: Kevin Kalinsky, MD, MS, FASCO +++
https://www.medscape.org/viewarticle/1002880?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260215-OUS-HONC-1002880-cta
Keyboard typing test could help diagnose Parkinson’s disease early
New software and hardware tools that collect data while a person types can detect fine motor impairment — a possible sign of neurodegeneration.
https://www.drugdiscoverynews.com/keyboard-typing-test-could-help-diagnose-parkinson-s-disease-early-16713?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9jRV2zkFBGFtv7ZuNtKvBMnqlRdAAhsAITRI_X8Yff65KpDf0dcuQ1BKQ5-lQAtlnGZW2srRGlVE7phxe4aeDKL39jTQ&_hsmi=403918635&utm_content=403918635&utm_source=hs_email
A new Parkinson’s disease treatment that adapts to the brain
The FDA approved Medtronic’s adaptive deep brain stimulation system, which delivers electrical stimulation in real time based on the brain’s state.
https://www.drugdiscoverynews.com/a-new-parkinson-s-disease-treatment-that-adapts-to-the-brain-16384?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9B9nWvgDzw34gRM8fwTPDFYg3So-fLxbbpLX6ULAGIg0J6tdoxERYuNXf11BaXtUdjkt0_w0WCdacBLORogALeSvd2aQ&_hsmi=403918635&utm_content=403918635&utm_source=hs_email
domingo, 15 de febrero de 2026
Functional Food
Functional Food
This hub provides a comprehensive overview and the latest news on functional foods, superfoods, and dietary components that contribute to health and disease prevention. The collection highlights bioactive compounds in foods such as lychee, chia seeds, dates, baobab fruit, and black sesame, alongside evidence-based discussions on fermented foods, postbiotics, and algae-based supplements. Readers will also find insights into the health benefits of traditional and modern diets, including the Atlantic and Washoku patterns, as well as functional beverages and plant-derived oils. By combining nutritional science, clinical research, and updates on emerging food innovations, this hub equips healthcare professionals, researchers, and health-conscious individuals with reliable knowledge to evaluate functional foods and their role in supporting long-term wellness.
https://www.news-medical.net/condition/Functional-Food
Cardiologists highlight overlooked heart risks across women’s lives +++
Daily coffee intake linked to fewer atrial fibrillation relapses
https://www.news-medical.net/news/20260130/Daily-coffee-intake-linked-to-fewer-atrial-fibrillation-relapses.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_8_february_2026
The study reveals that moderate coffee consumption may lower atrial fibrillation recurrence risk post-cardioversion, highlighting coffee's potential benefits.
New model predicts redo surgery risk in adult congenital heart disease
https://www.news-medical.net/news/20260131/New-model-predicts-redo-surgery-risk-in-adult-congenital-heart-disease.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_8_february_2026
Heart specialists at Mayo Clinic today presented new research at the 2026 Society of Thoracic Surgeons Annual Meeting that redo surgery for adults with congenital heart disease (CHD) remains high-risk, and a clinically applicable national risk assessment model is needed to help patients and care teams make decisions about procedures.
Cardiologists highlight overlooked heart risks across women’s lives
https://www.news-medical.net/news/20260203/Cardiologists-highlight-overlooked-heart-risks-across-womene28099s-lives.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_8_february_2026
Heart disease remains the leading cause of death for women in the United States, yet awareness of cardiovascular risk—particularly among younger women and women of color—has stalled, even as rates of high blood pressure, diabetes, obesity, and high cholesterol continue to rise.
Men develop premature heart disease earlier than women
https://www.news-medical.net/news/20260202/Men-develop-premature-heart-disease-earlier-than-women.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_8_february_2026
Researchers track heart disease from young adulthood to uncover when sex-based risk differences first emerge.
In a recent study published in the Journal of the American Heart Association, a group of researchers examined sex-based differences in the age of onset of premature cardiovascular disease (CVD) and its major subtypes across adulthood.
Why cardiologist evaluation matters after non-cardiac surgery
https://www.news-medical.net/news/20260203/Why-cardiologist-evaluation-matters-after-non-cardiac-surgery.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_8_february_2026
Many post-surgical heart injuries go unnoticed, but cardiologist input can change outcomes.
In a recent study published in the European Heart Journal, researchers analyzed data from more than 1,000 patients who developed perioperative myocardial injury to explain the potential mortality benefits of including a cardiologist in non-cardiac procedures, particularly for high-risk patients.
Engineered Listeria boosts innate immunity against cancer
https://www.news-medical.net/news/20260213/Engineered-Listeria-boosts-innate-immunity-against-cancer.aspx
After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.
US drinking water kiosks sometimes contain elevated lead levels
https://www.news-medical.net/news/20260213/US-drinking-water-kiosks-sometimes-contain-elevated-lead-levels.aspx
After high-profile water crises like the one in Flint, Michigan, some Americans distrust the safety of tap water, choosing to purchase drinking water from freestanding water vending machines or kiosks. Yet this more expensive water may contain different pollutants than local tap water, according to a study in ACS' Environmental Science & Technology. Researchers report that water sampled from 20 kiosks in six states sometimes contained lead at levels above public health recommendations.
Vitamin A and thyroid hormones in the retina shape fetal vision
https://www.news-medical.net/news/20260213/Vitamin-A-and-thyroid-hormones-in-the-retina-shape-fetal-vision.aspx
Humans develop sharp vision during early fetal development thanks to an interplay between a vitamin A derivative and thyroid hormones in the retina, Johns Hopkins University scientists have found.
Ozempic users continue treatment when weight loss works despite side effects
https://www.news-medical.net/news/20260213/Ozempic-users-continue-treatment-when-weight-loss-works-despite-side-effects.aspx
An examination of user reviews finds that people continue off-label Ozempic when it delivers results, even if side effects persist.
A recent study in the Journal of Medical Internet Research examined patients’ experiences with off-label Ozempic use for weight loss and identified factors that influence user satisfaction and treatment discontinuation.
Stopping vertical transmission requires global resolve The Lancet Microbe ++... ++
Stopping vertical transmission requires global resolve
The Lancet Microbe
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00273-3/fulltext?dgcid=raven_jbs_etoc_email
Feb 2026
Volume 7Number 2
https://www.thelancet.com/journals/lanmic/issue/vol7no2/PIIS2666-5247(26)X2001-8
Convergence and global molecular epidemiology of Klebsiella pneumoniae plasmids harbouring the iuc3 virulence locus: a population genomic analysis
Marjorie J Gibbon, PhDa,∗ ∙ Natacha Couto, PhDa,b,∗ ∙ Keira Cozens, MSca ∙ Samia Habib, PhDa ∙ Lauren Cowley, PhDa ∙ Prof David M Aanensen, PhDb ∙ et al.
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00164-8/fulltext?dgcid=raven_jbs_etoc_feature_lanmic
Impact of a multicomponent training intervention (Clean FrontLine) on microbiological cleanliness in Cambodian referral hospitals: a multicentre, stepped-wedge, cluster-randomised trial
Giorgia Gon, PhDa giorgia.gon@lshtm.ac.uk ∙ Sokvy Ma, MScb ∙ Alexander M Aiken, PhDa ∙ Prof Stephanie J Dancer, PhDc ∙ Prof Wendy J Graham, PhDa ∙ Stephen Nash, MScd ∙ et al.
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00190-9/fulltext?dgcid=raven_jbs_etoc_feature_lanmic
Nonmetastatic nasopharyngeal carcinoma: in search of safer therapies The Lancet Regional Health – Americas +++ +...
E-cigarettes versus combination nicotine replacement therapy following a recent failed quit attempt: a pragmatic randomized trial through state tobacco quitlines
Theodore L. Wagenera katrina.vickerman@gmail.com ∙ Alice Hintona ∙ Theodore M. Braskya ∙ Yoo Jin Choa ∙ Laura A. Beebeb ∙ Michael S. Businelleb ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00362-X/fulltext?dgcid=raven_jbs_etoc_feature_lanam
Incidence rates of twelve chronic diseases/conditions in US adults: findings from a population-based study
Richard L. Nahina Nahinr@mail.nih.gov ∙ Termeh Feinbergb ∙ Hanna Grol-Prokopczykc ∙ Flavia P. Kaposd ∙ Kerri Murraye ∙ Remle Scottf ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00353-9/fulltext?dgcid=raven_jbs_etoc_feature_lanam
Nonmetastatic nasopharyngeal carcinoma: in search of safer therapies
The Lancet Regional Health – Americas
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00050-5/fulltext?dgcid=raven_jbs_etoc_email
Feb 2026
Volume 54
https://www.thelancet.com/journals/lanam/issue/vol54nonull/PIIS2667-193X(25)X0013-2
Beyond Cure: Long-Term Risks After Childhood Cancer ++++ +++ International Childhood Cancer Day
Late Effects
Beyond Cure: Long-Term Risks After Childhood Cancer
Cured as Children, At Risk as Adults? Long-Term Outcomes After Childhood Cancer
Maurie Markman, MD
https://www.medscape.com/viewarticle/cured-children-risk-adults-long-term-outcomes-after-2026a10000dr?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
January 30, 2026
Certain Childhood Cancer Therapies Tied to Valvulopathy
Certain Childhood Cancer Therapies Tied to Valvulopathy
Edited by Gargi Mukherjee
https://www.medscape.com/viewarticle/certain-childhood-cancer-therapies-tied-valvulopathy-2025a1000rh6?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
October 13, 2025
1 in 3 Childhood Cancer Survivors Face Endocrine Issues
1 in 3 Childhood Cancer Survivors Face Endocrine Issues
Edited by Vinod Rane, BS Pharm
https://www.medscape.com/viewarticle/1-3-childhood-cancer-survivors-face-endocrine-issues-2026a10002bc?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
Medscape UK
January 27, 2026
Childhood Cancer Survivors Face Long-Term Meningioma Risk
Childhood Cancer Survivors Face Long-Term Meningioma Risk
Edited by Gargi Mukherjee
https://www.medscape.com/viewarticle/childhood-cancer-survivors-face-long-term-meningioma-risk-2025a1001026?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
December 22, 2025
Support & Prevention
Teen Exercise May Reshape Breast Cancer Risk
Teen Exercise May Reshape Breast Cancer Risk
Edited by Katie Lennon
https://www.medscape.com/viewarticle/teen-exercise-may-reshape-breast-cancer-risk-2026a10002ji?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
January 27, 2026
The Lingering Fear After Beating Childhood Cancer
The Lingering Fear After Beating Childhood Cancer
Maurie Markman, MD
https://www.medscape.com/viewarticle/lingering-fear-after-beating-childhood-cancer-2025a10006qo?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
April 01, 2025
Travel Help Announced for Families of Children With Cancer
Travel Help Announced for Families of Children With Cancer
Dr Sheena Meredith
https://www.medscape.com/viewarticle/travel-help-announced-families-children-cancer-2026a10003e1?ecd=mkm_ret_260215_mscpmrk-OUS_InFocus_etid8099638&uac=148436CN&impID=8099638
Medscape UK
February 03, 2026
sábado, 14 de febrero de 2026
Editorial e1 Management of diabetes during pregnancy The Lancet Obstetrics, Gynaecology, & Women's Health +++...
Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial
Jessie Gommers, MSca,b ∙ Veronica Hernström, MDb,c ∙ Viktoria Josefsson, MDb,c ∙ Hanna Sartor, PhDb,d ∙ David Schmidt, MDb,d ∙ Annie Hjelmgren, MDd ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02464-X/abstract?utm_campaign=infocusalerts-obgyn&utm_medium=email&dgcid=hubspot_email_infocusalerts-obgyn_feature&_hsenc=p2ANqtz-_7M80FSuvslzvwWswPk3Na_r7ibyL7ZWu-Yyskp5PkSgptvk--XgD6AVn4ZqB_lVgX0b_yfgEwflgJOIOShdkZbORCyA&_hsmi=403618992&utm_content=403597469&utm_source=hs_email
Epidemiological and genetic evidence for shared mechanisms between migraine and pre-eclampsia: a nationwide cohort and genetic risk study in Denmark
Olafur B Davidsson, PhDa,b,c,d oda@cancer.dk ∙ Klaus Rostgaard, MSca,b ∙ Ragnar P Kristjánsson, PhDb,c,d,e ∙ Jojo Biel-Nielsen Dietz, MD PhDb ∙ Noomi Vainer, MDb ∙ Lisette J A Kogelman, PhDc,d ∙ et al.
https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00114-1/abstract?utm_campaign=infocusalerts-obgyn&utm_medium=email&dgcid=hubspot_email_infocusalerts-obgyn_feature&_hsenc=p2ANqtz-9wnhB4dqgJZHH1LzfzNxDpAIEL_AFDcwlALnxma_7O-4sP49NMGtP6s5DSOh5NvtvVh_j8rOuLhX7hTpc-K5r9IPSgMQ&_hsmi=403618992&utm_content=403597469&utm_source=hs_email
Editorial
e1
Management of diabetes during pregnancy
The Lancet Obstetrics, Gynaecology, & Women's Health
https://www.thelancet.com/journals/lanogw/issue/vol2no1/PIIS3050-5038(25)X0006-6
From Cookies To Caregivers: 7 Types Of Grandparents By Ivanhoe Broadcast News on February 20, 2026
https://www.ivanhoe.com/?p=36685&preview=1&_ppp=2dbe0e6937
Orlando, Fla. (Ivanhoe Newswire) — By age 65, AARP reports 96 percent of Americans are grandparents. Grandparents play an important role in children’s lives. Studies show kids who have close relationships with grandparents have fewer emotional and behavioral problems and better social skills. Now, researchers have identified seven distinct grandparenting styles and chances are, you might recognize yourself in more than one of them.
Are You Scam Proof? Who Is Really At Risk? By Ivanhoe Broadcast News on February 19, 2026
https://www.ivanhoe.com/?p=36682&preview=1&_ppp=ca5851d049
Orlando, Fla. (Ivanhoe Newswire) — The New York Times reports Americans over 70 control $53 trillion in wealth and cybercrime against elders is skyrocketing! The Federal Trade Commission reports older adults lost 2.4 billion dollars to scams last year, a sharp increase from just a few years ago. Now, a new study is taking a closer look at what really makes someone vulnerable and why even people who think they’re scam-proof may not be.
Modern Love: Dating Trends Redefining Valentine’s Day By Ivanhoe Broadcast News on February 18, 2026
https://www.ivanhoe.com/?p=36679&preview=1&_ppp=b8b66a7765
Orlando, Fla. (Ivanhoe Newswire) — About 60 percent of people worldwide celebrate Valentine’s Day but for many, the holiday is no longer just about romantic love. From friendship-first celebrations to new dating rules and tech-driven matchmaking, the way people connect is evolving.
Love, Lies, And Money: Inside Today’s Romance Scams By Ivanhoe Broadcast News on February 17, 2026
https://www.ivanhoe.com/?p=36676&preview=1&_ppp=56641a44c9
Orlando, Fla. (Ivanhoe Newswire) — Worldwide, nearly one in four people say they’ve been scammed online. One of the fastest growing, and most devastating type is the romance scam, where fraudsters pretend to fall in love, then ask for money. It’s now the third most common scam targeting adults 60 and older.
Fuel Like A Champion By Ivanhoe Broadcast News on February 16, 2026
https://www.ivanhoe.com/?p=36673&preview=1&_ppp=23b3277d32
Orlando, Fla. (Ivanhoe Newswire) — While the world is watching the Winter Olympics, there’s a lot more going on behind the scenes than gold medals and record-breaking runs. Olympians are training and fueling their bodies for peak performance. But experts say you don’t have to be an elite athlete to apply some of those same principles to your own workouts.
Popular weight-loss drugs linked to rare 'pirate disease,' researchers warn By Angelica Stabile Fox News Published February 13, 2026 7:00am EST
Popular weight-loss drugs linked to rare 'pirate disease,' researchers warn
GLP-1 medications may contribute to malnutrition as clinical trials fail to monitor food intake
Angelica Stabile By Angelica Stabile Fox News
Published February 13, 2026 7:00am EST
https://www.foxnews.com/health/popular-weight-loss-drugs-linked-rare-pirate-disease-scurvy-researchers-warn?lid=zoopmps49qu6
James Van Der Beek’s death highlights alarming colon cancer rise in younger adults By Angelica Stabile , Melissa Rudy Fox News Published February 12, 2026 2:41pm EST
James Van Der Beek’s death highlights alarming colon cancer rise in younger adults
Doctors reveal why colon cancer is now the top deadliest cancer among those 50 and under
Angelica Stabile By Angelica Stabile , Melissa Rudy Fox News
Published February 12, 2026 2:41pm EST
https://www.foxnews.com/health/james-van-der-beeks-death-highlights-alarming-colon-cancer-rise-younger-adults?lid=hz6ixf6p5dwy
Revisiting concepts of mitochondrial transport and energy metabolism in health and cancer Salvatore Passarella* [1]
https://www.academia.edu/2837-4010/3/4/10.20935/AcadBiol8065
Although our understanding of mitochondrial processes has expanded substantially, the contributions of metabolite transport and energy metabolism to mitochondrial function in health and disease remain incompletely characterized. The transport and metabolism of key metabolites, including oxaloacetate, L-lactate and D-lactate, are mediated by distinct transporters and mitochondrial enzymes that together influence cellular bioenergetics in normal and neoplastic tissues. This review reassesses mechanistic aspects of mitochondrial shuttles, gluconeogenesis and the Cori cycle, the mitochondrial transport and oxidation of L-lactate, the Warburg effect, and the methylglyoxal pathway. Emphasis is placed on evidence supporting mitochondrial uptake and metabolism of oxaloacetate and lactate isomers and on the implications of these processes for redox balance, anaplerosis, and biosynthesis in cancer. I propose that a fuller integration of metabolite transport phenomena into models of cellular metabolism is necessary to refine current concepts of mitochondrial physiology and pathophysiology.
The need for echocardiographic reference values in adults over 80 years of age
Miguel Quintana, Mira Carling, Anders Olofsson, Dag Isaksson, Jenny Fahlen, Elin Kärrman, Fredrik Pihl, Roland Forsberg, Björn Persson, Alen Lovric, Thomas Gustafsson, Karin Bouma
Volume 4, Issue 1
https://www.academia.edu/journals/academia-biology/articles?source=journal-top-nav
Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms
https://www.fda.gov/consumers/consumer-updates/hormone-replacement-therapies-can-help-women-bothersome-menopausal-symptoms?utm_medium=email&utm_source=govdelivery
The effects of menopause can make a woman’s daily life much harder, and therapies approved by the U.S. Food and Drug Administration can help. But too many women might not use these treatments to lessen their menopause symptoms because of the risks associated with these drugs described in the drug labels’ boxed warnings (the FDA’s most prominent warnings).
viernes, 13 de febrero de 2026
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs. Specifically, risk statements related to cardiovascular disease, breast cancer and probable dementia were removed from the “boxed warning,” the agency’s most prominent safety-related warning.
“This decision reflects our commitment to follow the science wherever it leads and to correct course when the evidence demands it,” Health and Human Services Secretary Robert F. Kennedy, Jr. said. “By removing these boxed warnings, we ensure that women receive accurate information about hormone therapy—free from exaggeration or fear. A healthcare system worthy of public trust tells the truth, updates its guidance as science evolves, and respects women’s ability to make informed choices about their own health.”
The FDA initiated the removal of these warnings in November 2025, following a comprehensive review of the scientific literature. At the FDA’s request, 29 drug companies have submitted proposed labeling changes. This first batch of six products with approved labeling changes includes products from each of the four categories of HRT for menopausal women:
Systemic combination therapy (estrogen and progestogen)
Systemic estrogen-alone therapy
Systemic progestogen-alone therapy for women with a uterus using systemic estrogen
Topical vaginal estrogen therapy
“With today’s action, we are delivering on our promise to make sure women have accurate, scientifically grounded information about the potentially life-changing benefits of HRT,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Women face symptoms of menopause that can last for years, and our efforts will help these women make well-informed medical decisions.”
Menopause is a normal life stage, but its symptoms can significantly reduce quality of life. Common symptoms include hot flashes and night sweats (called vasomotor symptoms or VMS); vaginal, vulvar, and urinary tract changes caused by lower estrogen levels; and osteoporosis (thinning bones), which increases fracture risk.
The FDA has approved multiple hormone therapies for moderate-to-severe hot flashes, vaginal dryness and discomfort, and preventing bone loss. In addition, randomized studies show that women who initiate HRT within 10 years of the onset of menopause (generally before age 60) have a reduction in all-cause mortality and fractures. Just a small fraction of women who could benefit from these treatments, however, are using them. In 2020, about 41 million U.S. women were ages 45–64 — yet only about 2 million women ages 46–65 received a hormone-therapy prescription.
Today’s action will allow women, working with their health care professionals, to make better-informed decisions about their treatment plan for menopause symptoms. Women are encouraged to consult the drug label, available here, for more detailed information about the benefits and risks of these products.
Menopausal Hormone Therapies with Updated Prescribing Information
https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information?utm_medium=email&utm_source=govdelivery
Statin safety: when warnings outlive the evidence The Lancet ++... ´+
Statin safety: when warnings outlive the evidence
The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00303-X/fulltext?dgcid=raven_jbs_etoc_email
Feb 14, 2026
Volume 407Number 10529p649-732
https://www.thelancet.com/journals/lancet/issue/vol407no10529/PIIS0140-6736(26)X2004-9
Tetanus
Prof Önder Ergönül, MD MPHa,b oergonul@ku.edu.tr ∙ Selin Kolsuz, MDa ∙ Prof J Peter Figueroa, MBBS PhD
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01579-X/abstract?dgcid=raven_jbs_etoc_feature_lancet
Thawing a Frozen Shoulder Arif Musa, MD; Ali Harb, MD | February 4, 2026 |
https://reference.medscape.com/slideshow/Frozen-Shoulder-6019131?ecd=wnl_critimg_260213_mscpref_etid8099014&uac=148436CN&impID=8099014
Frozen shoulder is a condition marked by progressive stiffness and pain that eventually resolves through a "thawing" phase. While traditional treatments range from physical therapy to surgery, new techniques like Adhesive Capsulitis Embolization (ACE) offer additional relief. This presentation reviews current treatment efficacy and new clinical developments.
Alcohol guidance in US dietary guidelines: a step backwards The Lancet Gastroenterology & Hepatology ++... ++
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00016-6/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 11Number 3p175-266, e2-e5
https://www.thelancet.com/journals/langas/issue/vol11no3/PIIS2468-1253(26)X2001-5
Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study
Nathaniel A Cohen, MDa nathanielac@tlvmc.gov.il ∙ Prof Dominik Bettenworth, MDb,c ∙ Neta Sror, MDd ∙ Raneem Khedraki, PhDe ∙ Qijun Yang, MSe ∙ Prof Maria T Abreu, MDf ∙ et al.
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00347-4/abstract?dgcid=raven_jbs_etoc_feature_langas
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
Eva Visser, MD PhDa ∙ Maud A Reijntjes, MD PhDa ∙ Lianne Heuthorst, MD PhDa ∙ Merle E Stellingwerf, MD PhDa ∙ Rachel West, MD PhDb ∙ Koen van Dongen, MD PhDc ∙ et al.
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00291-2/abstract?dgcid=raven_jbs_etoc_feature_langas
Editorial e75 GLP-1 receptor agonists in rheumatic disease The Lancet Rheumatology ++... +
Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial
Prof David J Beard, DPhila,d david.beard@ndorms.ox.ac.uk ∙ Loretta J Davies, DPhila ∙ Prof Jonathan A Cook, PhDa ∙ Prof Graeme MacLennan, MScc ∙ Jemma Hudson, PhDc ∙ Prof Andrew J Price, FRCSa ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00250-4/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsenc=p2ANqtz-8EvPIK-fX0yJMuYr9c9Nwpm9DIZRxFz0gOGNEBqrxbEH7fNoROnm7ue3Totl3pYHkiyW_KNOoBIDS2jgAY5gRQeicV4w&_hsmi=403170350&utm_content=402699227&utm_source=hs_email
Editorial
e75
GLP-1 receptor agonists in rheumatic disease
The Lancet Rheumatology
https://www.thelancet.com/journals/lanrhe/issue/vol8no2/PIIS2665-9913(26)X2001-X
Trends in mortality due to haemophagocytic lymphohistiocytosis across 29 European countries from 2011 to 2021: a retrospective, international, population-based study
Leher Gumber, MSca,b ∙ Reza Omidvar, MScc ∙ Francesca Gonnelli, PhDd,e ∙ Adam Taylor, MEngc ∙ Thomas Trimble, BScc ∙ Mark Bishton, PhDe,f ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00292-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsenc=p2ANqtz-9aoZkd0o9FGb_nWrlnoJRWFpic0JTPGPQ8_H80f5KTTSL4xH3EWoRoQCgcTqDH1rl4l3LjAYNXar7gys7ODjs8TLebRw&_hsmi=403170350&utm_content=402699227&utm_source=hs_email
Gene therapy startups push past old limits to reach more patients With gene therapy now a clinical reality, innovators are designing delivery systems that can sustain lifelong correction, handle complex genes, and make treatments accessible to more patients. +++++
https://www.drugdiscoverynews.com/gene-therapy-startups-push-past-old-limits-to-reach-more-patients-17003
In 2026, drug discovery faces a higher bar
Biopharma’s recovery is real, but the data show a sector that now rewards validated biology, late-stage execution, and commercial relevance.
https://www.drugdiscoverynews.com/in-2026-drug-discovery-faces-a-higher-bar-16997
A faster route to active GPCRs
GPCRs drive a huge portion of today’s drug market, but producing them in a functional form remains a major bottleneck for discovery and structural studies.
https://www.drugdiscoverynews.com/a-faster-route-to-active-gpcrs-16977
Exploring the tiny robots improving drug delivery from inside the body
Moved by magnets or ultrasound waves, these tiny robots make delivering drugs more accurate and effective.
https://www.drugdiscoverynews.com/exploring-the-tiny-robots-improving-drug-delivery-from-inside-the-body-16998
Sustained-release drug delivery targets pediatric inherited retinal disease
PolyActiva and RareSight are pairing pro-drug chemistry with targeted ocular delivery to address early-stage barriers in rare pediatric retinal disorders.
https://www.drugdiscoverynews.com/sustained-release-drug-delivery-targets-pediatric-inherited-retinal-disease-16945
Suscribirse a:
Comentarios (Atom)
